AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02089932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia.
Study NCT02089932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02559635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bowel stimulation
Description: Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
Study NCT02559635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestle Resource
Description: Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
Study NCT00724659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
Study NCT00724659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
Study NCT02017899 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04072172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mole Freckle Pen
Description: Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
Study NCT02836483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg, QD
Description: Oral administration
Study NCT02836483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 400mg, BID
Description: Oral administration
Study NCT02836483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg, BID
Description: Oral administration
Study NCT02836483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tubes 3~5Tablet, QD
Description: Oral administration
Study NCT02808897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard drainage
Description: One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (Fr) shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
Study NCT02808897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Tube Clearance drainage
Description: One (1) PleuraFlow chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 Fr shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
Study NCT02836483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyvox 600mg, BID
Description: Oral administration
Study NCT02836483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 1200mg, QD
Description: Oral administration
Study NCT03940560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duramesh Suturable Mesh
Description: Use of Duramesh Suturable Mesh for internal load bearing closures
Study NCT00558636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib + Paclitaxel + Carboplatin
Description: Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), \[400 mg, (2 tablets x 200 mg each) orally, twice daily\] on Study Days 2-19 and paclitaxel (175 mg/m\^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
Study NCT00558636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Paclitaxel + Carboplatin
Description: Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m\^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
Study NCT00716001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Study NCT00716001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine
Study NCT02663154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatherapy inhaler
Description: Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
Study NCT02663154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline inhaler
Description: Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
Study NCT03679390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.
Study NCT02523287 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Description: Randomized assignment
Study NCT02564029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Single dose
Study NCT02564029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06372865 and placebo for lorazepam
Study NCT02564029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: 2 mg single oral dose
Study NCT04063072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
Study NCT03625154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ankle open reduction internal fixation
Description: Open Reduction and Internal Fixation with plates and screws
Study NCT03625154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non operative management
Description: closed reduction and splinting followed by progressive weight bearing
Study NCT00903370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MVS
Description: All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
Study NCT02523287 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Randomized assignment
Study NCT00903370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MVS
Description: All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
Study NCT00903370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
Study NCT03909555 — intervention group
Intervention type: OTHER
Intervention: Complications assessment
Description: Records of cardiovascular diseases (CVD), carotid ultrasonography, electrocardiogram, echocardiography, fundus photography, urinary albumin excretion, Toronto Clinical Neuropathy Scale and Composite Autonomic Symptom Score.
Study NCT04319419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement with micronutrients
Description: Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.
Study NCT04319419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Group received nutrition education program during 6 months
Study NCT02227849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (TA-7284)
Description: The patients will receive Canagliflozin orally for 52 weeks
Study NCT05261659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy and Targeted memory reactivation during REM sleep
Description: Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
Study NCT05261659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
Study NCT04116593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
Study NCT01321008 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
Study NCT01321008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
Study NCT01321008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
Study NCT01321008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
Study NCT01321008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg by mouth daily on Days 1-5 of a 21 day cycle.
Study NCT04463303 — intervention group
Intervention type: OTHER
Intervention: lung ultrasound
Description: patient with or without weaning induced pulmonary adema
Study NCT02399735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose NK cells ×4 times
Description: Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
Study NCT02399735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal Dose NK cells ×4 times
Description: Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
Study NCT02399735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal Dose NK cells ×8 times
Description: Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
Study NCT00467636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose monitoring
Description: Regular pre and post meal blood glucose monitoring.
Study NCT00467636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI > 30 = 0.2 unit/kg)
Study NCT00727727 — intervention group
Intervention type: DRUG
Intervention: Piribedil
Study NCT03166683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement
Study NCT03166683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care include other sealant / hemostatic devices as patches or liquid/gels
Study NCT01767961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnostic imaging
Description: Undergo MBS
Study NCT01767961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Correlative studies
Study NCT04904172 — intervention group
Intervention type: DEVICE
Intervention: Masimo O3 Regional Oximetry
Description: wo electrodes will be attached to the forehead area and connected to the Near Infrared Spectroscopy device after the consent of the patients who apply to Ege University Hospital Emergency Service with acute ischemic stroke and who are planned to have intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments, and / or their caregivers.
Study NCT04681989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving On After Breast Cancer
Description: After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~1. Instructions on how to use the physical therapy-based education materials by a research staff member~2. a range of motion wand~3. a small ball~4. MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment.
Study NCT00835289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Description: Omax3\[TM\] (Cenestra Health \[TM\]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
Study NCT00835289 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules of matching corn oil placebo
Study NCT01767961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Correlative studies
Study NCT02722213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR).
Description: MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
Study NCT04460183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301, a Nitric Oxide generating solution
Description: Product application requires inhalation using a standard handheld nebulizer.
Study NCT04460183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive institutional SOC for the treatment of COVID-19.
Study NCT04460183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive institutional SOC for the treatment of COVID-19.
Study NCT00225914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
Study NCT00225914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
Study NCT03372161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-102
Description: injection
Study NCT03372161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection
Study NCT02941614 — intervention group
Intervention type: BEHAVIORAL
Intervention: Distress screening
Description: A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
Study NCT02012803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture
Description: Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
Study NCT02012803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment of achilles tendon rupture
Description: Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
Study NCT02227849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 analogue
Study NCT01988506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
Study NCT03533127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01008
Description: LY01008+Carboplatin/Paclitaxel
Study NCT02821325 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.~2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2.
Study NCT03284060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program
Description: Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~1. pen and paper tasks focusing on specific emotion recognition component (20 min),~2. computerized tasks focusing on the same process (20 min),~3. a proposal of a home-based task (during 20 min).
Study NCT00856323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).